Is dihexa safe?
Short-term tolerability looks decent in user reports. Long-term: unknown, with one real mechanism-level concern. Dihexa amplifies HGF signaling at the c-MET receptor; that pathway drives lung, gastric, hepatocellular, and renal cancers. Anyone with personal or family history of those should skip it. No trial-validated human safety data.
Last reviewed · Panya.health editorial
What dihexa actually is
Dihexa is a small angiotensin IV-derived peptide developed at Washington State University by Joseph Harding's lab as a potential Alzheimer's therapeutic. McCoy 2013 and Benoist 2014 showed it amplifies hepatocyte growth factor (HGF) signaling at the c-MET receptor and drives dendritic spine formation in rat hippocampal slices, with the bench measurement being roughly 7 orders of magnitude more potent than BDNF on that specific assay. Wright 2017 framed the Alzheimer's-target case. Human Phase 1 was filed but never published readouts. The compound is orally active, crosses the blood-brain barrier, and has been sold in the research-chem space since the late 2010s under the name dihexa or PNB-0408.
The cancer-pathway concern, in plain terms
HGF/c-MET is one of the most-studied driver pathways in human cancer. Gherardi 2012 in Nature Reviews Cancer is the canonical review. c-MET amplification is established as an oncogenic driver in lung adenocarcinoma, gastric cancer, hepatocellular carcinoma, and renal cell carcinoma. The major pharmaceutical investment in HGF/c-MET INHIBITORS (capmatinib, tepotinib, savolitinib) exists precisely because shutting this pathway DOWN slows cancer. Dihexa is designed to potentiate the same pathway. A potent HGF amplifier with no human safety data is therefore a real bet against an unknown personal cancer-risk profile. Anyone with a history of c-MET-driven cancer, family history of those tumor types, or known c-MET-amplified disease should not touch this. The community framing of dihexa as 'just a stronger BDNF' obscures the mechanism-level distinction.
Other things to know
No dose-response data in humans. Community practice runs 8 to 45 mg per day oral on an empty stomach, in 4 to 8 week cycles. Stacking with semax or noopept is common but unvalidated. Pregnancy and breastfeeding off-limits by default. No cardiovascular safety data. No drug interaction profile. Quality control on what is sold under the dihexa name varies because the molecule is rarely synthesized at scale; COA review matters more than for compounds with mature supply chains. WADA-banned via S0 for athletes.
Where Panya stands
Dihexa is documented at panya.health/peptide/dihexa with the full mechanism, evidence, and risk profile. Panya does NOT yet route to vendors for dihexa anywhere because non-GLP-1 vendor scoring is gated on lawyer review. The page lists community-mentioned suppliers without endorsement. The framing on the page leads with the cancer-pathway concern because that is the actual risk picture, not because we are advising for or against use.
Read about this peptide
Related posts
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
The five things that matter on a COA, the three things that do not, and the one question that separates a serious vendor from a cargo-cult operator.
The clinic route costs more and takes longer. The research-chem route puts more on you. Neither is wrong. Here is how to choose.
People who asked this also asked
The tools behind the answer
The answer for your situation.
The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.